Shenzhen Kaifa Technology
920029
Kunshan Kinglai Hygienic Materials
300260
THEC
833509
4
DHNM
839792
5
Beijing Yupont Electric Power Technology
688597
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.